Table 1

Patient characteristics and clinical features

Total (n=72)dc-SSc (n=25)lc-SSc (n=47)p Value
Age (mean±SD)61±1161±1361±11NS
Sex (F:M)60:1217:843:4<0.05
Phase (early/established)27/459/1618/29NS
ANA (%)9710096NS
ACA/Anti-topo I/anti-RNApol I-III27/26/14/18/123/8/0<0.001
mRSS (median, range)5 (0–25)15 (0–25)4 (0–22)<0.0001
Pulmonary involvement (%)38 (53)17 (68)21 (45)NS
Gastroenteric involvement (%)37 (52)15 (60)22 (48)NS
Disease activity1 (0–6)1 (0–6)0.5 (0–3)<0.05
General severity index0 (0–2)0 (0–2)0 (0–2)NS
  • ACA, anticentromere antibodies; ANA, antinuclear antibodies; dc-SSc diffuse cutaneous SSc; lc, limited cutaneous SSc; mRSS, modified Rodnan Skin Score; NS, not significant; SSc, systemic sclerosis.